Bristol-Myers delivered another all-around beat as the management continued to make an effort to expand its new product range and inline franchise. In this quarter, the inline and new product portfolio grew by 13%, and the company managed to deliver non-GAAP EPS growth of 3%. They also got the approval of Sotyktu, the first-in-class TYK2 inhibitor for psoriasis, and the company managed to close its Turning Point acquisition. This acquisition added a new product to the product line of the company ....
